Breaking News Headlines Today | Ground News

See every side of every news story

pharmatimes.com image

News from pharmatimes.com

pharmatimes.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

Is pharmatimes.com credible or reliable? Our Factuality score answers both of those questions. When it comes to pharmatimes.com, we’ve assigned a Unknown factuality rating. Ratings are assigned by aggregating scores from Ad Fontes Media and Media Bias/Fact Check.

Information about pharmatimes.com

Where is pharmatimes.com located?pharmatimes.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top pharmatimes.com News

UCB's Bimekizumab Shows Sustained Efficacy Against HS Abscesses, Tunnels, and Pain Over 3 Years

Asheville · Asheville

UCB's Bimekizumab Shows Sustained Efficacy Against HS Abscesses, Tunnels, and Pain Over 3 Years

100% Center coverage: 3 sources

UCB reveals three-year data on bimekizumab, showcasing significant pain relief and lesion resolution in hidradenitis suppurativa patients at the 2025 SHSA.See the Story

Breakthrough Five-Year Outcomes: Vamorolone Shows Promising Positive Results in Duchenne Muscular Dystrophy Treatment

Breakthrough Five-Year Outcomes: Vamorolone Shows Promising Positive Results in Duchenne Muscular Dystrophy Treatment

100% Right coverage: 1 sources

Archyde Vamorolone Demonstrates Sustained Benefit in Duchenne Muscular Dystrophy, New Data Reveal New Findings from the Guardian study indicate that Vamorolone, a novel corticosteroid treatment for Duchenne muscular dystrophy (Dmd), is… You can read the full story here: Breakthrough Five-Year Outcomes: Vamorolone Shows Promising Positive Results in Duchenne Muscular Dystrophy Treatment.See the Story

CNX Therapeutics Acquires Sativex From Jazz Pharmaceuticals – RamaOnHealthcare

CNX Therapeutics Acquires Sativex From Jazz Pharmaceuticals – RamaOnHealthcare

Deal strengthens CNS portfolio and ensures continuity of access for MS patientsCNX Therapeutics has acquired the global Sativex (nabiximols) business from Jazz Pharmaceuticals, reinforcing its position in the central nervous system (CNS) therapeutic space. The transaction was completed on 31 October 2025 and includes marketing authorisations, commercial partnerships and manufacturing arrangements.Sativex is approved in the [...]See the Story

Breaking News Topics Related to pharmatimes.com